Oruka Therapeutics, Inc. (ORKA)
| Market Cap | 5.31B +311.6% |
| Revenue (ttm) | n/a |
| Net Income | -109.69M |
| EPS | -2.02 |
| Shares Out | 66.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 513,993 |
| Open | 81.15 |
| Previous Close | 81.15 |
| Day's Range | 79.07 - 81.15 |
| 52-Week Range | 25.23 - 115.52 |
| Beta | -0.11 |
| Analysts | Strong Buy |
| Price Target | 155.00 (+93.39%) |
| Est. Earnings | Nov 11, 2026 |
About ORKA
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for ORKA stock is "Strong Buy." The 12-month stock price target is $155.0, which is an increase of 93.39% from the latest price.
News
Oruka Therapeutics ORKA-001 data meet base case, says Clear Street
Clear Street says Oruka Therapeutics (ORKA)’ ORKA-001 update today met its base case. PASI 100 increased to 71.4% at week 28 from the “class-leading” 63.5% rate at week 16 despite…
Oruka Therapeutics announces Week 28 results for ORKA-001
Oruka Therapeutics (ORKA) announced positive Week 28 results from its EVERLAST-A Phase 2a trial of ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody, in moderate-to-severe plaque psori...
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4 Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001 ...
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
MENLO PARK, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standa...
Oruka Therapeutics appoints Todd Edwards as chief commercial officer
Oruka Therapeutics (ORKA) announced the appointment of Todd Edwards as chief commercial officer, effective August 24. Edwards joins Oruka from Arcutis Biotherapeutics (ARQT), where he served as execut...
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
MENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standar...
Oruka Therapeutics files $1B mixed securities shelf
16:20 EDT Oruka Therapeutics (ORKA) files $1B mixed securities shelf
Oruka Therapeutics Registration statement: Registration filing
Oruka Therapeutics filed a registration statement on August 21, 2026, providing details about a securities offering with the SEC.
Oruka Therapeutics reports Q2 EPS (55c), consensus (50c)
“The second quarter and recent months were highly productive as we advanced both of our co-lead programs toward a series of important readouts,” said Lawrence Klein, Chief Executive Officer of…
Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026 EVERLAST-B fully enrolled ahead of schedule, with Week 16 data now expected in 4Q 20...
Oruka Therapeutics Earnings release: Q2 2026
Oruka Therapeutics released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Oruka Therapeutics Quarterly report: Q2 2026
Oruka Therapeutics has published its Q2 2026 quarterly earnings report on August 10, 2026.
Oruka Therapeutics falls -8.1%
Oruka Therapeutics (ORKA) is down -8.1%, or -$7.60 to $85.69.
Oruka Therapeutics price target raised to $130 from $100 at UBS
UBS raised the firm’s price target on Oruka Therapeutics (ORKA) to $130 from $100 and keeps a Buy rating on the shares. Oruka Therapeutics is undervalued ahead of upcoming second…
Oruka Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing best-in-class IL-23 and IL-17A/F therapies for psoriatic disease, with phase II data showing high efficacy and flexible dosing options. Key upcoming milestones include additional EVERLAST-A data, phase III readiness, and expansion into new indications, all supported by strong financials.
Oruka Therapeutics Transcript: AGM 2026
The meeting confirmed a quorum and addressed three proposals: director elections, auditor ratification, and executive compensation. All proposals passed, with final vote totals to be filed with the SEC.
Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
MENLO PARK, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard...
Oruka Therapeutics reports Q1 EPS (48c), consensus (54c)
“This was an important period for our company as we saw interim data for ORKA-001 that hit the upper end of our expectations on all aspects,” said Lawrence Klein, Chief…
Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026
Oruka Therapeutics Quarterly report: Q1 2026
Oruka Therapeutics has published its Q1 2026 quarterly earnings report on May 13, 2026.
Oruka Therapeutics Earnings release: Q1 2026
Oruka Therapeutics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis
Halozyme (HALO) and Oruka Therapeutics (ORKA) announced that Halozyme’s wholly-owned subsidiary, Halozyme Hypercon, has entered into a global exclusive collaboration and license agreement with Oruka. ...
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
Agreement provides exclusive rights for IL-23p19 in psoriatic disease and option for one additional target SAN DIEGO and MENLO PARK, Calif., May 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Na...
Oruka Therapeutics price target raised to $120 from $109 at Leerink
Leerink raised the firm’s price target on Oruka Therapeutics (ORKA) to $120 from $109 and keeps an Outperform rating on the shares.
Oruka Therapeutics price target raised to $120 from $75 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Oruka Therapeutics (ORKA) to $120 from $75 and keeps a Buy rating on the shares. The EVERLAST-A “delivers in spades,” positioning ORKA-001…